Merck, Inc.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 851
- Registration Number
- NCT06422143
- Locations
- 🇨🇳
Peking Union Medical College Hospital ( Site 2412), Beijing, Beijing, China
🇨🇳The First Affiliated hospital of Xiamen University-oncology ( Site 2420), Xiamen, Fujian, China
🇨🇳West China Hospital, Sichuan University ( Site 2422), Cheng Du, Sichuan, China
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06395090
- Locations
- 🇺🇸
Children's Mercy Hospital ( Site 2024), Kansas City, Missouri, United States
🇺🇸Children's Hospital of Philadelphia (CHOP) ( Site 2021), Philadelphia, Pennsylvania, United States
🇨🇳National Taiwan University Hospital ( Site 2983), Taipei, Taiwan
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1530
- Registration Number
- NCT06393374
- Locations
- 🇺🇸
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0041), Tulsa, Oklahoma, United States
🇦🇹Klinikum Wels-Grieskirchen GmbH ( Site 1205), Wels, Oberosterreich, Austria
🇫🇷Centre Antoine-Lacassagne ( Site 1308), Nice, Alpes-Maritimes, France
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06395103
- Locations
- 🇨🇳
National Taiwan University Hospital ( Site 1983), Taipei, Taiwan
🇺🇸Children's Mercy Hospital ( Site 1024), Kansas City, Missouri, United States
🇺🇸Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota, United States
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT06356311
- Locations
- 🇨🇳
Hunan Cancer Hospital ( Site 3014), Changsha, Hunan, China
🇨🇳Xinjiang Medical University Cancer Hospital - Urumchi-The No.11 of Surgery building ( Site 3010), Urumchi, Xinjiang, China
🇩🇪Städtisches Krankenhaus Kiel-2. Medizinische Klinik ( Site 1306), Kiel, Schleswig-Holstein, Germany
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06353386
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada
🇵🇱Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland
🇬🇧Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT06351631
- Locations
- 🇺🇸
UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo ( Site 2703), Alessandria, Italy
🇺🇸University of Michigan ( Site 6000), Ann Arbor, Michigan, United States
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06345729
- Locations
- 🇺🇸
Beverly Hills Cancer Center ( Site 0116), Beverly Hills, California, United States
🇺🇸Orchard Healthcare Research Inc. ( Site 0115), Skokie, Illinois, United States
🇺🇸St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings, Montana, United States
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06312176
- Locations
- 🇩🇰
Vejle Sygehus ( Site 1183), Vejle, Syddanmark, Denmark
🇳🇱Isala, locatie Zwolle ( Site 1525), Zwolle, Overijssel, Netherlands
🇵🇹Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1661), Lisbon, Lisboa, Portugal
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT06312137
- Locations
- 🇨🇳
Zhongshan Hospital of Fudan University ( Site 1325), Shangai, Shanghai, China
🇫🇷Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, France
🇫🇷Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, France